Click to learn more about our COVID-19 Vaccine Candidate SCB-2019 (CpG 1018/Alum)
Our vision is to deliver next-generation solutions to empower the global population with a healthier future.
Our mission is to leverage our cutting-edge Trimer-Tag™ technology platform and fully-integrated manufacturing capabilities for the discovery, development, and delivery of innovative and affordable medical solutions.
With our leading COVID-19 vaccine candidate SCB-2019 (CpG 1018/Alum), we expect to commercialize one of the first protein-based COVID-19 vaccines globally, enabling us to potentially help address the global shortage of COVID-19 vaccines.
The Trimer-Tag™ technology platform can trimerize any protein of interest and target a broad spectrum of naturally trimerization-dependent disease and biologic targets.
We have built our product pipeline by employing the Trimer-Tag™ technology platform.
Clover Biopharmaceuticals Completes Enrollment of Adult and Elderly Population in SPECTRA Global Phase 2/3 Clinical Trial for its COVID-19 Vaccine Candidate
Clover Announces Advance Purchase Agreement with Gavi for Over 400 Million Doses of Clover’s COVID-19 Vaccine for the COVAX Facility
Clover and Dynavax Announce Commercial Supply Agreement of Dynavax’s CpG 1018 Adjuvant for Clover’s COVID-19 Vaccine Candidate
Clover Announces Positive Preclinical Data for Second-Generation Protein-Based COVID-19 Vaccine Candidate Demonstrating Broad Neutralization Against Variants of Concern
